|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
PFAS (Forever Chemicals) Panel 2
Test Code14280
CPT Codes
82542<br>Restricted Client Code<br><strong>This test is not available for New York patient testing.</strong>
Preferred Specimen
2 mL serum collected in a no additive red-top tube
Minimum Volume
1 mL
Other Acceptable Specimens
Plasma collected in: EDTA (lavender-top) tube or EDTA (pink-top) tube • Serum collected in: No additive (royal blue-top) tube
Instructions
Sample collection devices coated with PTFE/Teflon® and PVDF should be avoided because of potential specimen contamination.
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 7 days
Refrigerated: 7 days
Frozen: 30 days
Refrigerated: 7 days
Frozen: 30 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis • Serum separator tube (SST) • Unspun whole blood • Non-approved tube types
Methodology
Mass Spectrometry (MS)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Tues, Sat; Report available: 10 days from receipt at performing laboratory
Reference Range
See Laboratory Report
Clinical Significance
Polyfluorinated alkyl substances (PFAS) are man-made forever chemicals that have been used in industry and consumer products since the 1940s. They have been used in nonstick cookware, water-repellent clothing, stain resistant fabrics and carpets, and some cosmetics and firefighting foams. PFAS do not break down. Scientists are still learning about the health effects to PFAS exposure. Some studies have shown that PFAS exposure may impact many different body systems. This panel will follow guidance provided by the National Academies of Sciences, Engineering, and Medicine (NASEM) Guidance on PFAS Exposure, Testing, and Clinical Follow-Up (2022) report on which PFAS to test and the corresponding clinical reference ranges.
References
1. National Academies of Sciences, Engineering, and Medicine 2022. Guidance on PFAS Exposure, Testing, and Clinical Follow-Up. Washington, DC: The National Academies Press. https://doi.org/10.17226/26156.
2. "What ATSDR is doing with PFAS Toxic Substances and Disease Registry, CDC, 14 July 2023, What ATSDR doing with PFAS
References
1. National Academies of Sciences, Engineering, and Medicine 2022. Guidance on PFAS Exposure, Testing, and Clinical Follow-Up. Washington, DC: The National Academies Press. https://doi.org/10.17226/26156.
2. "What ATSDR is doing with PFAS Toxic Substances and Disease Registry, CDC, 14 July 2023, What ATSDR doing with PFAS
